Beyond Air (NASDAQ:XAIR) Issues Earnings Results, Misses Estimates By $0.20 EPS

Beyond Air (NASDAQ:XAIR) announced its quarterly earnings data on Friday. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.20), Zacks reports. The firm had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $2.30 million. Beyond Air had a negative return on equity of 268.82% and a negative net margin of 447.75%.

Here are the key takeaways from Beyond Air’s conference call:

• Beyond Air said fiscal 2026 revenue rose 107% year over year to $7.7 million, with customer renewal rates of about 90%, signaling stronger adoption and retention for LungFit PH.
• The company reported a meaningful improvement in profitability metrics, including a $2 million swing to gross profit and a 35% improvement in operating results, helped by lower R&D and SG&A expenses.
• Management highlighted progress on the Gen 2 LungFit system, saying the FDA review remains on track and that potential approval could come in the second half of calendar 2026, with launch preparation underway for late 2026.
• The company expanded market access through a new national purchasing agreement with a top-three U.S. GPO, bringing its total to three major GPO relationships and broadening access to a substantial share of U.S. hospitals.
• Beyond Air issued first-time guidance of $8 million for calendar 2026 and $16 million-$18 million for calendar 2027, but the outlook assumes Gen 2 approval and commercialization in 2027 and still depends on FDA timing.

Beyond Air Price Performance

Shares of NASDAQ:XAIR opened at $0.49 on Friday. The firm has a market cap of $6.53 million, a price-to-earnings ratio of -0.11 and a beta of 0.26. The firm has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.81. Beyond Air has a fifty-two week low of $0.33 and a fifty-two week high of $4.78. The company has a debt-to-equity ratio of 2.65, a quick ratio of 4.77 and a current ratio of 5.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. purchased a new stake in Beyond Air during the third quarter valued at $1,753,000. Osaic Holdings Inc. grew its stake in shares of Beyond Air by 26.4% in the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after buying an additional 34,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Beyond Air by 57.5% in the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after buying an additional 24,695 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Beyond Air during the 3rd quarter valued at about $48,000. Institutional investors own 31.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on XAIR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beyond Air in a research report on Friday, April 24th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Beyond Air in a research note on Friday, March 27th. Finally, Wall Street Zen raised shares of Beyond Air to a “sell” rating in a research report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Beyond Air presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.